Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

The vaccine, called Nuvaxovid, is mainly intended for adults 65 or older. But people ages 12 to 64 with medical conditions that increase their risk of serious illness from COVID can also get the shot.